We demonstrate that specific blockade of PDGFRα is sufficient to reverse the aggressive phenotypic changes seen in PTC cells and this may represent an advance in therapy for those patients with progressive, metastatic disease. This evidence concerns the gene PDGFRA and metastatic neoplasm.